Dr. Amir Dehsarvi

Dr. Amir Dehsarvi

I am the Principal Scientist of Neuroimaging at Boehringer Ingelheim. My research focuses on the application of machine learning and deep learning to medical data, with a strong emphasis on leveraging neuroimaging to accelerate disease diagnosis and therapeutic target identification.

A systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease

Published in Alzheimer's & Dementia, vol 21, issue 10, pp e70783., 2025

This research systematically evaluated the predictive strength of longitudinal changes in Amyloid (A), Tau (T), and Neurodegeneration (N) biomarkers—specifically amyloid-PET, tau-PET, plasma phosphorylated tau at threonine 217 (p-tau217), and cortical thickness changes from MRI—for monitoring cognitive decline in Alzheimer’s disease. The study found that plasma p-tau217 and tau-PET changes, along with cortical thickness changes, accurately tracked cognitive decline, while amyloid-PET changes did not. This highlights plasma p-tau217 as a robust and cost-effective surrogate biomarker for monitoring treatment response and disease progression in AD trials.

Download paper here

Recommended citation: Biel, D., Steward, A., Dewenter, A., Dehsarvi, A., Zhu, Z., Roemer‐Cassiano, S. N., Frontzkowski, L., Hirsch, F., et al. (2025). A systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer’s disease. Alzheimer’s & Dementia, 21(10), e70783. https://doi.org/10.1002/alz.70783

Recommended citation: Biel, D., Steward, A., Dewenter, A., Dehsarvi, A., Zhu, Z., Roemer‐Cassiano, S. N., Frontzkowski, L., Hirsch, F., et al. (2025). A systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease. Alzheimer's & Dementia, 21(10), e70783. https://doi.org/10.1002/alz.70783
Download Paper